IP Library › Granted Patent US 12,715,923
Granted Patent B2
US 12,715,923 · App. 17/586,977 · Granted Aug 25, 2026

Antibodies binding to GPRC5D

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,715,923
App. No.
17/586,977
Filed
Jan 28, 2022
Granted
Aug 25, 2026
Kind
B2
Art Unit
1646
USPC
424/136.1
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: FAUTI, TANJA; KLEIN, CHRISTIAN; MAYOUX, MAUD LÉA; SCHNEIDER, ANNELIESE; HAEGEL, HÉLÈNE CÉCILE
To: ROCHE GLYCART AG
Reel/Frame 065758/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: ROCHE GLYCART AG
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 065759/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: BUJOTZEK, ALEXANDER; CHRISTOPEIT, TONY; FERTIG, GEORG; KRAFT, THOMAS; LORENZ, STEFAN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 065759/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 065759/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 065759/0452 →
Priority Claims (1)
EP 19189255 · Jul 31, 2019 · regional
Continuity (2)
Continuation PCTEP2020071182 · Jul 28, 2020
Related Publication 20220259318A1 · Aug 18, 2022
References Cited (157)
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591828A · Bosslet et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 11591397B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11608376B2 · Georges et al. · 2023 [cited by applicant]
US 11672858B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11780920B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 12215155B2 · Freimoser-Grundschober et al. · 2025 [cited by applicant]
US 12466889B2 · Bujotzek et al. · 2025 [cited by applicant]
US 12473373B2 · Freimoser-Grundschober et al. · 2025 [cited by applicant]
US 20080069820A1 · Fuh et al. · 2008 [cited by applicant]
US 20160075785A1 · Ast et al. · 2016 [cited by applicant]
US 20170306044A1 · Vu et al. · 2017 [cited by applicant]
US 20180037651A1 · Attar · 2018 [cited by examiner]
US 20190367612A1 · Chaen et al. · 2019 [cited by applicant]
US 20200199234A1 · Georges et al. · 2020 [cited by applicant]
US 20200270347A1 · Freimoser-Grundschober et al. · 2020 [cited by applicant]
US 20210403562A1 · Freimoser-Grundschober et al. · 2021 [cited by applicant]
US 20220010014A1 · Freimoser-Grundschober et al. · 2022 [cited by applicant]
US 20220213199A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20220259318A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20230159642A1 · Bujotzek et al. · 2023 [cited by applicant]
US 20230277662A1 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 20230416365A1 · Georges et al. · 2023 [cited by applicant]
US 20230416411A1 · Bruenker et al. · 2023 [cited by applicant]
US 20240042022A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
US 20240043535A1 · Amann et al. · 2024 [cited by applicant]
US 20240132590A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
US 20250277035A1 · Freimoser-Grundschober et al. · 2025 [cited by applicant]
CA 3052938A1 · 2018 [cited by applicant]
CL 2020001854A1 · 2020 [cited by applicant]
CN 104936986A · 2015 [cited by applicant]
CN 105143270A · 2015 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
EP 1870459B1 · 2016 [cited by applicant]
EP 2992012B1 · 2019 [cited by examiner]
EP 3581651A1 · 2019 [cited by applicant]
EP 3749692A1 · 2020 [cited by applicant]
JP 2017536341A · 2017 [cited by applicant]
JP 2018504890A · 2018 [cited by applicant]
TW 201936641A · 2019 [cited by applicant]
TW I829667B · 2024 [cited by applicant]
WO WO9301161A1 · 1993 [cited by applicant]
WO WO9316185A2 · 1993 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO9850431A3 · 1999 [cited by applicant]
WO WO0177342A1 · 2001 [cited by applicant]
WO WO2004106381A1 · 2004 [cited by applicant]
WO WO2005061547A2 · 2005 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007147901A1 · 2007 [cited by applicant]
WO WO2008024715A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2010112193A1 · 2010 [cited by applicant]
WO WO2010115589A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010136172A1 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010129304A3 · 2011 [cited by applicant]
WO WO2011034605A2 · 2011 [cited by applicant]
WO WO2011090754A1 · 2011 [cited by applicant]
WO WO2011090762A1 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012058768A8 · 2012 [cited by applicant]
WO WO2012130831A1 · 2012 [cited by applicant]
WO WO2013026831A1 · 2013 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026839A1 · 2013 [cited by applicant]
WO WO2013096291A2 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013157954A1 · 2013 [cited by applicant]
WO WO2014131694A1 · 2014 [cited by applicant]
WO WO2014131712A1 · 2014 [cited by applicant]
WO WO2015095539A1 · 2015 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2016005593A1 · 2016 [cited by applicant]
WO WO2016016299A1 · 2016 [cited by applicant]
WO WO2016020309A1 · 2016 [cited by applicant]
WO WO2016055593A1 · 2016 [cited by applicant]
WO WO2016062734A1 · 2016 [cited by applicant]
WO WO2016090329A2 · 2016 [cited by applicant]
WO WO2016166629A1 · 2016 [cited by applicant]
WO WO2016172485A2 · 2016 [cited by applicant]
WO WO2018017786A2 · 2018 [cited by applicant]
WO WO2018060301A1 · 2018 [cited by applicant]
WO WO2018147245A1 · 2018 [cited by examiner]
WO WO2019086497A2 · 2019 [cited by applicant]
WO WO2019122046A1 · 2019 [cited by applicant]
WO WO2019122060A1 · 2019 [cited by applicant]
WO WO2019154890A1 · 2019 [cited by examiner]
WO WO2019220368A1 · 2019 [cited by applicant]
WO WO2020092854A2 · 2020 [cited by applicant]
WO WO2020127618A1 · 2020 [cited by applicant]
WO WO2020127619A1 · 2020 [cited by examiner]
WO WO2020148677A1 · 2020 [cited by applicant]
WO WO2021018859A2 · 2021 [cited by applicant]
WO WO2021255138A1 · 2021 [cited by applicant]
WO WO2021255143A1 · 2021 [cited by applicant]
WO WO2021255146A1 · 2021 [cited by applicant]
WO WO2022079138A1 · 2022 [cited by examiner]
WO WO2014110601A1 · 2024 [cited by applicant]
Derksen, “Illegitimate WNT signaling promotes proliferation of multiple myeloma cells,” PNAS 101(16):6122-7 (2004). [cited by applicant]
Dirks, “Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer,” Journal of Clinical Oncology. 26(17):2916-2924 (2008). [cited by applicant]
López-Lázaro, “The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis,” Oncoscience. 2(5):467-75 (2015). [cited by applicant]
Tran, “Survival comparison between glioblastoma multiforme and other incurable cancers,” Journal of Clinical Neuroscience. 17(4):417-21 (2010). [cited by applicant]
U.S. Appl. No. 19/000,912, Hoffmann-La Roche Inc. [cited by applicant]
“Human GPRC5D APC-conjugated Antibody,” R&D Systems, retrieved from<https://resources.rndsystems.com/pdfs/datasheets/fab6300a.pdf>, revised Feb. 6, 2018 (2015) (1 page). [cited by applicant]
Atamaniuk et al., “Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma,” Eur J Clin Invest. 42(9):953-60 (2012). [cited by applicant]
Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” J Mol Biol. 270(1):26-35 (1997). [cited by applicant]
Bacac et al., “CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors,” AACR 106th Annual Meeting, Apr. 18-22, Philadelphia, PA. 75(15) Abstract 2481 (2015) … [cited by applicant]
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G [cited by applicant]
Bräuner-Osborne et al., “Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D,” Biochim Biophys Acta. 1518(3):237-48 (2001). [cited by applicant]
Carter, “Bispecific human IgG by design,” J Immunol Methods. 248(1-2):7-15 (2001). [cited by applicant]
Cohen et al., “GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells,” Hematology. 18(6):348-51 (2013) (5 pages). [cited by applicant]
Gao et al., “Comparative Transcriptome Analysis of Fetal Skin Reveals Key Genes Related to Hair Follicle Morphogenesis in Cashmere Goats,” PLoS One. 11(3):e0151118, retrieved from <https://www.ncbi.nlm.nih.gov/pmc/artic… [cited by applicant]
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Heeley et al., “Mutations Flanking the Polyglutamine Repeat in the Modulatory Domain of Rat Glucocorticoid Receptor Lead to an Increase in Affinity for Hormone,” Endocr Res. 28(3):217-229 (2002). [cited by applicant]
Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci U S A. 90(14):6444-48 (1993). [cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Eng. 9(3):299-305 (1996). [cited by applicant]
Hudson et al., “Engineered Antibodies,” [cited by applicant]
Inoue et al., “The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures,” J Invest Dermatol. 122(3):565-73 (2004). [cited by applicant]
Johnson et al., “Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion,” J Mol Biol. 399(3):436-49, retrieved from <https://science… [cited by applicant]
Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J Mol Biol. 293(1):41-56 (1999). [cited by applicant]
Klein et al., “The use of CrossMAb technology for the generation of bi- and multispecific antibodies,” MAbs. 8(6):1010-20 (2016). [cited by applicant]
Kodama et al., “Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma,” Mol Cancer Ther. 18(9):1555-64, retrieved from <https://aacrjournals.org/mct/article/18/9/1555/92691/Anti-GP… [cited by applicant]
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,” J Immunol. 148(5):1547-53 (1992). [cited by applicant]
Liljeblad et al., “Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance,” Glycoconj J. 17(5):323-9 (2000). [cited by applicant]
Lombardi et al., “Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease,” Genes Chromosomes Cancer. 46(3):226-38 (2007). [cited by applicant]
Milstein et al., “Hybrid Hybridomas and Their Use in Immunohistochemistry,” Nature. 305(5934):537-40 (1983). [cited by applicant]
Moreau et al., “Multiple myeloma—translation of trial results into reality,” Lancet. 388(10040):111-3 (2016). [cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. 317(9):1255-60 (2011). [cited by applicant]
Pillarisetti et al., “A T-cell redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma,” Blood. 135(15):1232-43, retrieved from <https://www.ncbi.nlm.nih.gov/pmc/artic… [cited by applicant]
Plückthun, “Chapter 11: Antibodies from [cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody C [cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci U S A. 108(27):11187-92 (2011). [cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev. 36(6):458-67 (2010). [cited by applicant]
Smith et al., “GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells,” available in PMC Sep. 22, 2020, published in final edited form as: Sci Transl Med. 11(485): eaau7746, re… [cited by applicant]
Spiess et al., “Alternative molecular formats and therapeutic applications for bispecific antibodies,” Mol Immunol. 67(2 Pt A):95-106, retrieved from <https://www.sciencedirect.com/science/article/pii/S016158901500005X?… [cited by applicant]
Tai et al., “Targeting B-cell maturation antigen in multiple myeloma,” Immunotherapy. 7(11):1187-99, retrieved from <https://ncbi.nlm.nih.gov/pmc/articles/PMC4976846/> Apr. 5, 2022 (2015) (17 pages). [cited by applicant]
Tutt et al., “Trispecific F(ab′) [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2020/071182, issued Feb. 1, 2022 (13 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2020/071182, mailed Aug. 4, 2021 (23 pages). [cited by applicant]
Bacac et al. “CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors,” Oncoimmunology. 5(8 Suppl e1203498) (2016) (3 pages). [cited by applicant]